(Q36656464)

15 August 2017

1 reference

title

Using translational medicine to understand clinical differences between botulinum toxin formulations (English)

1 reference

15 August 2017

main subject

translational medicine

1 reference

K R Aoki

1

1 reference

15 August 2017

D Ranoux

series ordinal

2

1 reference

15 August 2017

J Wissel

series ordinal

3

1 reference

15 August 2017

publication date

1 December 2006

1 reference

European Journal of Neurology

15 August 2017

published in

1 reference

15 August 2017

volume

13 Suppl 4

1 reference

15 August 2017

page(s)

10-19

1 reference

Botulinum toxin: a successful therapeutic protein

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

SV2 is the protein receptor for botulinum neurotoxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Identification of the major steps in botulinum toxin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Safety of botulinum toxin type A: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Selective location of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Pharmacology and immunology of botulinum toxin type A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Neuromuscular effects distant from the site of botulinum neurotoxin injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Combined intraarterial cisplatin infusion and radiation therapy for invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Botulinum toxin A treatment of adult upper and lower limb spasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2006.01649.X

10.1111/J.1468-1331.2006.01649.X

21 January 2018

Identifiers

DOI

1 reference

release_bhrxkwj4i5bzjkc37xbiecipam

15 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bhrxkwj4i5bzjkc37xbiecipam

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference